Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MLYCD | O95822 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12189529 | 0.95 | TDP1 (0.57) | TDP1HPGDMAPTNPC1TP53 | |
| SCHEMBL12172824 | 0.84 | NPSR1 (0.72) | TDP1HPGDMAPTTSHRNPSR1 | |
| SCHEMBL5053005 | 0.80 | KDM4E (0.62) | TDP1HPGDMAPTNPC1TP53 | |
| SCHEMBL5053292 | 0.80 | KDM4E (0.59) | TDP1HPGDMAPTNPC1TP53 | |
| SCHEMBL1490952 | 0.76 | HPGD (0.76) | TDP1HPGDMAPTNPC1TP53 | |
| SCHEMBL1394361 | 0.74 | HPGD (0.72) | TDP1HPGDMAPTNPC1TP53 | |
| SCHEMBL4491643 | 0.74 | TDP1 (0.75) | TDP1HPGDMAPTNPC1TP53 | |
| SCHEMBL11089749 | 0.73 | HPGD (0.68) | TDP1HPGDMAPTNPC1TP53 | |
| SCHEMBL1403631 | 0.73 | ALDH1A1 (0.63) | TDP1HPGDMAPTNPC1TSHR | |
| SCHEMBL2422719 | 0.73 | TDP1 (0.73) | TDP1HPGDMAPTNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8859620-B2 | Phthalanilate compounds and methods of use | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
| WO-2011026107-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | TDP1 2961/4885HPGD 926/4885MAPT 2792/4885 |
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | TDP1 2961/4885HPGD 926/4885MAPT 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.